Quote
106.20
+1.63 (+1.56%)
We have scored 94 news catalysts on ABT (ABT) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.25). Most of the impact sits in sector healthcare and price momentum.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
104.60–106.85
Open
106.15
Prev close
104.57
Volume
8.4M
Avg volume
—
Dividend
—
IPO
—
No scored news tagged ABT or its network in the window yet.
Show more ABT articles →Analysts publish price targets on ABT, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
7 analyst price targets from $112 to $134
as of 2026-09-12
The market is 16% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about ABT — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of ABT, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for ABT: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The price sits 16% below the median published target and at the very bottom of the model range, meaning the market has fully absorbed recent beats but refuses to pay for the sustained high growth the bulls require.
What the disagreement turns on
Can Abbott's medical devices segment and Exact Sciences integration actually deliver the 10%+ revenue growth needed to justify a 32.8 times earnings multiple, and the wired data can only partially settle this by tracking segment unit volumes.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $102 on 2026-09-12 — 51 days ago.
